Want to join the conversation?
Predictive analytics solutions provider $VRSK said its 4Q15 results were in line with expectations with an increase in diluted adjusted EPS of about 23%. Full year revenue grew 18% and diluted adjusted EPS rose about 29%. $VRSK grew the topline, excluding the Healthcare Analytics business and recent acquisitions, over 5% in 4Q15 and 7% in 2015.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.